Treat and Extend Versus Treat and Observe Regimens in Wet Age-related Macular Degeneration Patients Treated with Ranibizumab: 3-year Surveillance Period

Copyright: © 2014 Calvo P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Treat and Extend Versus Treat and Observe Regimens in Wet Agerelated Macular Degeneration Patients Treated with Ranibizumab: 3-year Surveillance Period Pilar Calvo1*, Yao Wang2, Antonio Ferreras1, Wai-Ching Lam3, Robert Devenyi3 and Michael H Brent3 1Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain 2Faculty of Medicine, University of Toronto, Canada 3Department of Ophthalmology and Vision Sciences, University of Toronto, Canada